At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 56 enrolled
Drug / intervention
Corticosteroid +2 moredrug
Likely dose
Corticosteroid 20 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Double Blinded Prospective Pilot Study to Determine the Safety and Effectiveness of a Connective Tissue Allograft (ActiveMatrix) vs. Standard of Care in Adhesive Capsulitis of the Shoulder
The University of Texas Health Science Center, Houston·interventional·Posted May 6, 2023·Updated Mar 5, 2026
In Brief
A Phase 4 clinical trial evaluating Corticosteroid, ActiveMatrix, and 1 other intervention for Adhesive Capsulitis. Completed, enrolled 56 participants across 1 site.
Detailed Summary
The purpose of this study is to compare ActiveMatrix® to standard of care corticosteroid injection in the treatment of adhesive capsulitis of the shoulder (frozen shoulder).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAdhesive Capsulitis
CountriesUnited States
CollaboratorsSkye Biologics, Inc.
Timeline
Phase 4CompletedFinished
2023202420252026
Enrollment StartJan 2023
First PostedMay 2023
Primary CompletionFeb 2025
TodayJul 2026
First PostedMay 6, 2023
Enrollment StartJan 3, 2023
Primary CompletionFeb 4, 2025
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 3.2 years ago
Interventions
Corticosteroiddrug
Triamcinolone 20 mg (1cc)
ActiveMatrixother
1cc ActiveMatrix (Skye Biologics, Inc.)
Lidocainedrug
Lidocaine 10 mg/mL (5cc)